Accordingly, GLP-1 agonists administered in PD animal models showed beneficial effects, and, the first clinical trials presented encouraging results and suggest that these drugs may be considered as promising disease-modifying agents in PD (Athauda et al., 2017). The gene discussed is GCG; the disease is Parkinson disease.